Ronald K Ottichilo1,2, Christina S Polyak3,4, Bernard Guyah2, Benson Singa5, Josphat Nyataya1, Krista Yuhas6, Grace John-Stewart4,6,7,8, John N Waitumbi1. 1. US Army Medical Research Directorate-Kenya, Walter Reed Army Institute of Research/Kenya Medical Research Institute. 2. Department of Medical Immunology, Maseno University, Kisumu, Kenya. 3. Kenya Medical Research Institute, Nairobi. 4. US Military HIV Research Program, Henry Jackson Foundation, Walter Reed Army Institute of Research, Bethesda, Maryland. 5. Department of Medicine. 6. Department of Global Health. 7. Department of Pediatrics. 8. Department of Epidemiology, University of Washington, Seattle.
Abstract
BACKGROUND:Cotrimoxazole (CTX) discontinuation increases malaria incidence in human immunodeficiency virus (HIV)-infected individuals. Rates, quantity, and timing of parasitemia rebound following CTX remain undefined. METHODS:Serial specimens from a trial of HIV-infected individuals receiving antiretroviral treatment (ART) randomized to continue (the CTX arm) or discontinue (the STOP-CTX arm) were examined for malaria parasites by quantitative reverse transcription polymerase chain reaction (PCR). Specimens obtained at enrollment and then quarterly for 12 months and at sick visits were assessed; multiplicity of infection was evaluated by PCR that targeted the polymorphic msp-1/msp-2 alleles. RESULTS: Among 500 HIV-infected adults receiving ART (median ART duration, 4.5 years), 5% had detectable parasitemia at baseline. After randomization, parasite prevalence increased over time in the STOP-CTX arm, compared with the CTX arm, with values of 4% and <1%, respectively, at month 3, 8% and 2% at month 6, 14% and 2% at month 9, and 22% and 4% at month 12 (P = .0034). The combined mean parasite density at the various time points was higher in the STOP-CTX arm (4.42 vs 3.13 log10 parasites/mL; P < .001). The parasitemia incidence was 42.0 cases per 100 person-years in the STOP-CTX arm and 9.9 cases per 100 person-years in the CTX arm, with an incidence rate ratio of 4.3 (95% confidence interval, 2.7-7.1; P < .001). After enrollment, mixed infections (multiplicity of infection, >1) were only present in the STOP-CTX arm. CONCLUSION: Discontinuation of CTX by HIV-infected adults receiving ART resulted in progressive increases in malaria parasitemia prevalence and burden. CLINICAL TRIALS REGISTRATION: NCT01425073. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
RCT Entities:
BACKGROUND:Cotrimoxazole (CTX) discontinuation increases malaria incidence in human immunodeficiency virus (HIV)-infected individuals. Rates, quantity, and timing of parasitemia rebound following CTX remain undefined. METHODS: Serial specimens from a trial of HIV-infected individuals receiving antiretroviral treatment (ART) randomized to continue (the CTX arm) or discontinue (the STOP-CTX arm) were examined for malaria parasites by quantitative reverse transcription polymerase chain reaction (PCR). Specimens obtained at enrollment and then quarterly for 12 months and at sick visits were assessed; multiplicity of infection was evaluated by PCR that targeted the polymorphic msp-1/msp-2 alleles. RESULTS: Among 500 HIV-infected adults receiving ART (median ART duration, 4.5 years), 5% had detectable parasitemia at baseline. After randomization, parasite prevalence increased over time in the STOP-CTX arm, compared with the CTX arm, with values of 4% and <1%, respectively, at month 3, 8% and 2% at month 6, 14% and 2% at month 9, and 22% and 4% at month 12 (P = .0034). The combined mean parasite density at the various time points was higher in the STOP-CTX arm (4.42 vs 3.13 log10 parasites/mL; P < .001). The parasitemia incidence was 42.0 cases per 100 person-years in the STOP-CTX arm and 9.9 cases per 100 person-years in the CTX arm, with an incidence rate ratio of 4.3 (95% confidence interval, 2.7-7.1; P < .001). After enrollment, mixed infections (multiplicity of infection, >1) were only present in the STOP-CTX arm. CONCLUSION: Discontinuation of CTX by HIV-infected adults receiving ART resulted in progressive increases in malaria parasitemia prevalence and burden. CLINICAL TRIALS REGISTRATION: NCT01425073. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: John N Waitumbi; Jay Gerlach; Irina Afonina; Samuel B Anyona; Joseph N Koros; Joram Siangla; Irina Ankoudinova; Mitra Singhal; Kate Watts; Mark E Polhemus; Nicolaas M Vermeulen; Walt Mahoney; Matt Steele; Gonzalo J Domingo Journal: Trop Med Int Health Date: 2011-03-29 Impact factor: 2.622
Authors: Jonathan Mermin; John Lule; John Paul Ekwaru; Samuel Malamba; Robert Downing; Ray Ransom; Frank Kaharuza; David Culver; Francis Kizito; Rebecca Bunnell; Aminah Kigozi; Damalie Nakanjako; Winnie Wafula; Robert Quick Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Frederick N Baliraine; Yaw A Afrane; Dolphine A Amenya; Mariangela Bonizzoni; Anne M Vardo-Zalik; David M Menge; Andrew K Githeko; Guiyun Yan Journal: BMC Infect Dis Date: 2010-09-24 Impact factor: 3.090
Authors: Mary J Hamel; Carolyn Greene; Tom Chiller; Peter Ouma; Christina Polyak; Kephas Otieno; John Williamson; Ya Ping Shi; Daniel R Feikin; Barbara Marston; John T Brooks; Amanda Poe; Zhiyong Zhou; Benjamin Ochieng; Eric Mintz; Laurence Slutsker Journal: Am J Trop Med Hyg Date: 2008-09 Impact factor: 2.345
Authors: Moses R Kamya; Anne F Gasasira; Jane Achan; Tsedal Mebrahtu; Theodore Ruel; Adeodata Kekitiinwa; Edwin D Charlebois; Philip J Rosenthal; Diane Havlir; Grant Dorsey Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Bernadette Ng'eno; Ann Mwangi; Lucy Ng'ang'a; Andrea A Kim; Anthony Waruru; Irene Mukui; Evelyn W Ngugi; George W Rutherford Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: John N Waitumbi; Samuel B Anyona; Carol W Hunja; Carolyne M Kifude; Mark E Polhemus; Douglas S Walsh; Chris F Ockenhouse; D Gray Heppner; Amanda Leach; Marc Lievens; W Ripley Ballou; Joe D Cohen; Colin J Sutherland Journal: PLoS One Date: 2009-11-17 Impact factor: 3.240
Authors: Anne Liljander; Lisa Wiklund; Nicole Falk; Margaret Kweku; Andreas Mårtensson; Ingrid Felger; Anna Färnert Journal: Malar J Date: 2009-04-23 Impact factor: 2.979
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Randy G Mungwira; Matthew B Laurens; Wongani Nyangulu; Titus H Divala; Nginache Nampota-Nkomba; Andrea G Buchwald; Osward M Nyirenda; Edson Mwinjiwa; Maxwell Kanjala; Lufina Tsirizani Galileya; Dominique E Earland; Matthew Adams; Christopher V Plowe; Terrie E Taylor; Jane Mallewa; Joep J van Oosterhout; Miriam K Laufer Journal: AIDS Date: 2022-07-15 Impact factor: 4.632